Molecular Templates, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTEM research report →
Companywww.mtem.com
Molecular Templates, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform.
- CEO
- Eric E. Poma
- IPO
- 2005
- Employees
- 62
- HQ
- Austin, TX, US
Price Chart
Valuation
- Market Cap
- $658
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.61
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 87.94%
- Op Margin
- -18.26%
- Net Margin
- -14.18%
- ROE
- 148.79%
- ROIC
- -50.86%
Growth & Income
- Revenue
- $57.31M · 190.10%
- Net Income
- $-8,124,000 · 91.24%
- EPS
- $-1.80 · 92.73%
- Op Income
- $-10,466,000
- FCF YoY
- 54.44%
Performance & Tape
- 52W High
- $1.59
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.26
- Beta
- 1.53
- Avg Volume
- 2.43K
Get TickerSpark's AI analysis on MTEM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 24 | BIOTECH TARGET N V | sell | 1,279,820 |
| Sep 27, 24 | LALANDE KEVIN M. | other | 1,000 |
| Sep 27, 24 | Gruia Gabriela | other | 1,000 |
| Sep 27, 24 | SELICK HAROLD E | other | 1,000 |
| Sep 27, 24 | HOFFMANN DAVE | other | 1,000 |
| Sep 27, 24 | Sanders Corazon (Corsee) D. | other | 1,000 |
| Apr 2, 24 | BIOTECH TARGET N V | buy | 250,000 |
| Apr 2, 24 | BIOTECH TARGET N V | buy | 769,334 |
| Apr 2, 24 | BIOTECH TARGET N V | buy | 134,667 |
| Apr 2, 24 | LALANDE KEVIN M. | other | 1,154,154 |
Our MTEM Coverage
We haven't published any research on MTEM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MTEM Report →